Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXPFree Report) in a report released on Friday morning. The firm issued a sell rating on the stock.

Separately, Dawson James began coverage on Tonix Pharmaceuticals in a report on Wednesday, February 28th. They issued a buy rating and a $96.00 price objective for the company.

Check Out Our Latest Analysis on TNXP

Tonix Pharmaceuticals Stock Down 2.6 %

TNXP stock opened at $1.12 on Friday. The stock’s fifty day simple moving average is $4.87 and its two-hundred day simple moving average is $9.02. The company has a current ratio of 1.47, a quick ratio of 0.87 and a debt-to-equity ratio of 0.06. Tonix Pharmaceuticals has a 1-year low of $1.08 and a 1-year high of $60.16. The stock has a market cap of $3.35 million, a P/E ratio of -0.01 and a beta of 2.16.

Tonix Pharmaceuticals (NASDAQ:TNXPGet Free Report) last released its quarterly earnings data on Monday, May 13th. The company reported ($5.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($16.64) by $10.88. The company had revenue of $2.48 million for the quarter, compared to the consensus estimate of $4.00 million. Analysts expect that Tonix Pharmaceuticals will post -82.43 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC boosted its position in Tonix Pharmaceuticals by 160.0% during the 4th quarter. Armistice Capital LLC now owns 3,770,000 shares of the company’s stock valued at $1,519,000 after acquiring an additional 2,320,000 shares in the last quarter. Sabby Management LLC bought a new stake in Tonix Pharmaceuticals during the 3rd quarter valued at $680,000. Finally, Acadian Asset Management LLC boosted its position in Tonix Pharmaceuticals by 260.6% during the 1st quarter. Acadian Asset Management LLC now owns 335,373 shares of the company’s stock valued at $61,000 after acquiring an additional 242,358 shares in the last quarter. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

About Tonix Pharmaceuticals

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Featured Articles

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.